Abstract
More than 50% of the patients with Parkinson's disease (PD) may experience
mood disturbances. Serotonin-selective reuptake inhibitors (SSRI) are very
active in the management of depression. Citalopram is a new SSRI increasingly
used in the treatment of depression. The question of a negative impact of SSRI
on the motor function of patients with PD is an important clinical issue. A
number of such observations have published with various SSRI, but none,
up-to-now with citalopram. We report the case of a patient with PD who
experienced a worsening in the motor status soon after the addition of
citalopram to her antiparkinsonian drug regime. This single case report suggests
that this potential adverse event is a class related side effect.
Author Keywords: Parkinson's disease; Depression;
Serotonin-reuptake inhibitors; Citalopram
Cite or link using doi
Fax:
+34-9432-73732; email: neurotax@jet.es
